Opendata, web and dolomites

GREEN LINE

A non-antibiotic treatment for Acne and Onychomycosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GREEN LINE project word cloud

Explore the words cloud of the GREEN LINE project. It provides you a very rough idea of what is the project "GREEN LINE" about.

acute    infection    nail    boost    containing    fourth    13    global    sme    medical    patient    innovative    healthcare    community    opens    validation    notification    therapies    onychomycosis    completion       class    quality    risk    prevalent    difficult    mayor    instrument    fungi    treatments    destroy    concentrate    acne    eighth    commercialized    poor    solution    medicinal    additional    90    microbial    society    therapy    uses    mavena    absence    approval    ftes    line    revenues    thorugh    generating    reducing    viruses    disease    psycological    international    complete    teenagers    territory    advantages    48    treatment    market    clinical    peracids    efficiency    fungal    time    solutions    green    resistance    adherence    antibiotics    markets    respectively    prescription    health    10    once    population    efficacy    sold    negative    adults    diseases    roi    damage    worldwide    company    cosmetic    bacteria    physical    patients    life    care    limitations    skin    reduces    notfied    65   

Project "GREEN LINE" data sheet

The following table provides information about the project.

Coordinator
MAVENA INTERNATIONAL AG 

Organization address
address: BOSCH 67
city: HUNENBERG
postcode: 6331
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website https://mavena.com/news-detail-417/mavena-international-ag-im-forschungs-und-innovationsprogramm-der-eu-horizon-2020.html
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2018-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MAVENA INTERNATIONAL AG CH (HUNENBERG) coordinator 50˙000.00

Map

 Project objective

Acne and onychomycosis (nail fungal infection) are two of the most common skin diseases, affecting up to 90% of teenagers and 10% of adults, respectively. Acne is estimated to affect 9.4% of the global population, making it the eighth most prevalent disease worldwide. In addition to the health and cosmetic damage, there are psycological consequences for these patients, which have a great negative impact in quality of life. The current treatments for these diseases have limitations in terms of efficiency and side effects as well as containing antibiotics. As a result, there is poor patient adherence to these therapies contributing to increase the microbial resistance, a matter of great concern for global society. In response to this challenge, Mavena has developed innovative medical devices (Green Line) for the treatment of acne and onychomycosis. Green Line uses a novel concentrate of peracids which destroy bacteria, fungi and viruses thorugh a physical process. Green Line’s mayor advantages are its high efficacy compared to current solutions and the absence of antibiotics, improving therapy adherence and reducing the risk of microbial resistance. Green Line will be notfied as class III medical devices, and thus do not need such a long and difficult approval process as for a medicinal product. Moreover, after notification, Green Line medical devices can be sold within the whole European Community and do not require prescription. This reduces the time to the market and opens a large territory at once. Upon completion of the project, this solution will boost the growth of our company generating additional 13 FTEs, revenues of €65.1 M and a ROI of 7.48 by the fourth year after Phase 2 execution. With the help of the SME instrument, Mavena aims to complete the clinical validation of their product so that it can be commercialized across international markets, improving the quality of care of healthcare systems worldwide as well as the patient´s quality of life.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GREEN LINE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GREEN LINE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

PrasinoMed (2018)

First in the world ecological and sustainable cream for wound care, based on microalgaprasinococcus capsulatus

Read More  

GREEN WHS (2019)

NATURE FRIENDLY WATER HYDRAULIC STEERING SYSTEM

Read More  

PME Instrument v2 (2018)

Second generation chatbot development platform

Read More